Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Pravastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, was administered to nine hypercholesterolemic patients with diabetes mellitus to examine its effects on diabetic nephropathy. Pravastatin treatment resulted in lowering serum total cholesterol by 22.1% on the average (p less than 0.001), and led to a significant reduction in urinary excretion of albumin and beta 2-microglobulin in patients with an elevated urinary protein excretion rate at the baseline period. But glycemic control, blood pressure, urinary excretion of creatinine and that of N-acetyl-beta-D-glucosaminidase showed no significant change during the study. These results suggest that reduction of atherogenic lipids and lipoproteins with pravastatin could alleviate diabetic glomerular injury.
Sasaki
T
T
Third Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Kurata
H
H
Nomura
K
K
Utsunomiya
K
K
Ikeda
Y
Y
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D017035:Pravastatin; D011507:Proteinuria / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism
D000924:Anticholesteremic Agents; D001786:Blood Glucose; D006538:Heptanoic Acids; D008055:Lipids; D009281:Naphthalenes; D017035:Pravastatin